Core Insights - Defence Therapeutics Inc. has appointed Dr. Amie Phinney to its Board of Directors, effective immediately, to enhance governance and long-term value creation as the company advances its drug-delivery platform [1][2][3] Group 1: Leadership Changes - Dr. Phinney previously served as a Strategy and Business Advisor and will now play a crucial role on the Board, contributing to strategic priorities and governance [2][3] - The CEO of Defence Therapeutics, Sébastien Plouffe, emphasized Dr. Phinney's significant impact on the company's strategic direction and her valuable experience in global pharma and biotech [3] Group 2: Incentives and Compensation - The company has granted Dr. Phinney 100,000 incentive stock options, which are vested immediately and exercisable at a price of $0.75 per share for three years [4] Group 3: Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which allows for precision delivery to target cells, enhancing efficacy against cancer [5]
Defence Therapeutics Appoints Dr. Amie Phinney as Director